Cormick Gabriela, Ciapponi Agustín, Cafferata María Luisa, Belizán José M
Department of Mother and Child Health Research, Institute for Clinical Effectiveness and Health Policy (IECS), Dr. Emilio Ravignani 2024, Buenos Aires, Argentina, C1414CPV.
Cochrane Database Syst Rev. 2015 Jun 30;2015(6):CD010037. doi: 10.1002/14651858.CD010037.pub2.
Hypertension is a major public health problem that increases the risk of cardiovascular and kidney diseases. Several studies have shown an inverse association between calcium intake and blood pressure. As small reductions in blood pressure have been shown to produce rapid reductions in vascular disease risk even in individuals with normal blood pressure ranges, this review intends to evaluate the effect of calcium supplementation in normotensive individuals as a preventive health measure.
To assess the efficacy and safety of calcium supplementation versus placebo or control for reducing blood pressure in normotensive people.
We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomised controlled trials up to October 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched for inclusion in the Group's Specialised Register. We also reviewed reference lists from retrieved studies and contacted authors of relevant papers. We applied no language restrictions.
We selected trials that randomised normotensive people to dietary calcium interventions such as supplementation or food fortification versus placebo or control. We excluded quasi-random designs. The primary outcomes were hypertension (defined as blood pressure ≥ 140/90 mmHg) and blood pressure measures.
Two review authors independently selected trials for inclusion, abstracted the data and assessed the risks of bias.
We included 16 trials with 3048 participants. None of the studies reported hypertension as a dichotomous outcome. The effect on systolic and diastolic blood pressure was mean difference (MD) -1.43 mmHg (95% confidence interval (CI) -2.15 to -0.72) and -0.98 mmHg (95%CI -1.46 to -0.50) respectively. The effect on systolic and diastolic blood pressure for those younger than 35 years (7 trials with 399 participants) was -2.11 mmHg (95%CI -3.58 to -0.64) / -2.61 mmHg (95% CI -3.74, -1.49). The effect on systolic and diastolic blood pressure for those 35 years or more (9 trials with 2649 participants) was -0.96 mmHg (95%CI -1.83 to -0.09) / -0.59 mmHg (95%CI -1.13 to -0.06). The effect on systolic and diastolic blood pressure for women (6 trials with 1823 participants) was -1.45 mmHg (95% CI -2.78 to -0.12) / -0.92 mmHg (95% CI -1.71 to -0.14). The effect on systolic and diastolic blood pressure for men (5 trials with 617 participants) was -2.07 (95%CI -3.56 to -0.59] / -1.91 (95%CI -2.80 to -1.02).The quality of evidence for each of these outcomes was high. The effect is consistent in both genders regardless of baseline calcium intake.The effect on systolic blood pressure was 0.08 mmHg (95% CI -2.16 to 2.32) with doses less than 1000 mg, -1.14 mmHg (95% CI -2.01 to -0.27) with 1000 - 1500 mg, and -2.79 mmHg (95% CI -4.71 to -0.86) with more than 1500 mg. The effect on diastolic blood pressure was -0.54 mmHg (95% CI -2.23 to 1.15), -0.71 mmHg (95% CI -1.37 to -0.06) and -1.43 mmHg (95% CI -2.22 to -0.64) respectively. The quality of evidence for each of these outcomes was high.None of the studies reported adverse events.
AUTHORS' CONCLUSIONS: An increase in calcium intake slightly reduces both systolic and diastolic blood pressure in normotensive people, particularly in young people, suggesting a role in the prevention of hypertension. These results should be interpreted with caution, since the proposed biological mechanism explaining the relationship between calcium and blood pressure has not been fully confirmed. The effect across multiple prespecified subgroups and a possible dose response effect reinforce this conclusion. Even small reductions in blood pressure could have important health implications for reducing vascular disease.There is a great need for adequately-powered clinical trials randomising young people. Subgroup analysis should involve basal calcium intake, age, sex, basal blood pressure, and body mass index. We also require assessment of side effects, optimal doses and the best strategy to improve calcium intake.
高血压是一个主要的公共卫生问题,会增加心血管疾病和肾脏疾病的风险。多项研究表明钙摄入量与血压之间存在负相关。由于即使在血压正常范围内的个体中,血压的小幅降低也已显示出能迅速降低血管疾病风险,本综述旨在评估钙补充剂在血压正常个体中作为一种预防性健康措施的效果。
评估钙补充剂与安慰剂或对照相比,在血压正常人群中降低血压的疗效和安全性。
我们检索了Cochrane高血压组专业注册库、Cochrane对照试验中央注册库(CENTRAL)、MEDLINE、MEDLINE在研数据库、EMBASE和ClinicalTrials.gov,以查找截至2014年10月的随机对照试验。检索世界卫生组织国际临床试验注册平台(ICTRP)以纳入该组专业注册库。我们还查阅了检索到的研究的参考文献列表,并联系了相关论文的作者。我们没有应用语言限制。
我们选择将血压正常的人随机分配到饮食钙干预组(如补充剂或食品强化)与安慰剂或对照组的试验。我们排除了半随机设计。主要结局是高血压(定义为血压≥140/90 mmHg)和血压测量值。
两位综述作者独立选择纳入试验、提取数据并评估偏倚风险。
我们纳入了16项试验,共3048名参与者。没有研究将高血压作为二分法结局进行报告。对收缩压和舒张压的影响分别为平均差(MD)-1.43 mmHg(95%置信区间(CI)-2.15至-0.72)和-0.98 mmHg(95%CI -1.46至-0.50)。35岁以下人群(7项试验,399名参与者)对收缩压和舒张压的影响分别为-2.11 mmHg(95%CI -3.58至-0.64)/-2.61 mmHg(95%CI -3.74,-1.49)。35岁及以上人群(9项试验,2649名参与者)对收缩压和舒张压的影响分别为-0.96 mmHg(95%CI -1.83至-0.09)/-0.59 mmHg(95%CI -1.13至-0.06)。女性(6项试验,1823名参与者)对收缩压和舒张压的影响分别为-1.45 mmHg(95%CI -2.78至-0.12)/-0.92 mmHg(95%CI -1.71至-0.14)。男性(5项试验,617名参与者)对收缩压和舒张压的影响分别为-2.07(95%CI -3.56至-0.59)/-1.91(95%CI -2.80至-1.02)。这些结局中每项证据的质量都很高。无论基线钙摄入量如何,该效应在两性中都是一致的。剂量小于1000 mg时,对收缩压的影响为0.08 mmHg(95%CI -2.16至2.32);1000 - 1500 mg时,为-1.14 mmHg(95%CI -2.01至-0.27);超过1500 mg时,为-2.79 mmHg(95%CI -4.71至-0.86)。对舒张压的影响分别为-0.54 mmHg(95%CI -2.23至1.15)、-0.71 mmHg(95%CI -1.37至-0.06)和-1.43 mmHg(95%CI -2.22至-0.64)。这些结局中每项证据的质量都很高。没有研究报告不良事件。
钙摄入量的增加会使血压正常的人收缩压和舒张压略有降低,尤其是在年轻人中,这表明钙在预防高血压方面有作用。这些结果应谨慎解释,因为解释钙与血压之间关系的拟议生物学机制尚未得到充分证实。在多个预先设定的亚组中的效应以及可能的剂量反应效应强化了这一结论。即使血压的小幅降低对减少血管疾病也可能具有重要的健康意义。非常需要有足够样本量的随机对照试验来研究年轻人。亚组分析应涉及基础钙摄入量、年龄、性别、基础血压和体重指数。我们还需要评估副作用、最佳剂量以及改善钙摄入量的最佳策略。